The combination of OV-IL15C, an oncolytic HSV-1 that expresses IL15/IL15Rα fusion protein, and off-the-shelf EGFR-CAR-NK showed a synergism in inhibiting tumour growth and improving survival in mice compared to using either as monotherapy. Here, EGFR is linked to neoplasm.